VEXIM Receives ANVISA Approval for SpineJack Implants

VEXIM received regulatory approval from ANVISA to commercialize SpineJack® in Brazil for the treatment of vertebral compression fractures (VCFs).

VEXIM estimates that Brazil's VCF treatment market is valued at €15MM (~US $17MM). Export of SpineJack devices to the region will commence in coming months, following the product’s evaluation process...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us